Transplantation, HomologousBone Marrow TransplantationHematopoietic Stem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseHematologic NeoplasmsMyeloablative AgonistsWhole-Body IrradiationTransplantation, AutologousBone MarrowTissue DonorsGraft vs Tumor EffectHistocompatibility TestingTransplantation ChimeraTreatment OutcomeUnrelated DonorsBone Marrow CellsLeukemiaGraft vs Leukemia EffectRetrospective StudiesBusulfanGraft SurvivalHistocompatibilityRecurrenceLeukemia, Myeloid, AcuteVidarabineLiver TransplantationPeripheral Blood Stem Cell TransplantationStem Cell TransplantationChimerismSurvival AnalysisMyelodysplastic SyndromesCord Blood Stem Cell TransplantationImmunosuppressive AgentsRemission InductionHLA AntigensSiblingsSurvival RateLung DiseasesDonor SelectionAcute DiseaseMinor Histocompatibility AntigensHematologic DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaTime FactorsGraft RejectionDisease-Free SurvivalPostoperative ComplicationsHematopoietic Stem CellsCombined Modality TherapyAnemia, AplasticFollow-Up StudiesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCyclophosphamideCyclosporineKidney TransplantationT-LymphocytesImmunosuppressionLymphoma, Non-HodgkinBone and BonesAllograftsRisk FactorsSyndromeLymphocyte DepletionPulmonary AtelectasisTransplantation ImmunologyHematopoiesisTransplantation, IsogeneicMice, Inbred C57BLLiving DonorsPrognosisLymphomaHeart TransplantationBone Marrow PurgingLymphoproliferative DisordersMycophenolic AcidHepatic Veno-Occlusive DiseaseProspective StudiesTacrolimusCell TransplantationSalvage TherapyChronic DiseaseLung TransplantationCytomegalovirus InfectionsLeukemia, MyeloidIncidenceCohort StudiesMultiple MyelomaBone Marrow DiseasesRadiation ChimeraTransplantationAntineoplastic Combined Chemotherapy ProtocolsLymphocyte TransfusionAge FactorsSevere Combined ImmunodeficiencyAntineoplastic AgentsOrgan TransplantationAntilymphocyte SerumMice, Inbred BALB CGraft vs Host Reaction